Compound phenformin

A hypoglycemic drug and compound technology, which is applied in the field of compound hypoglycemic drugs, can solve problems such as diabetes syndrome and hypoglycemia, and achieve the effects of improving microcirculation, lowering blood pressure, and improving the state of ischemia and hypoxia

Inactive Publication Date: 2004-07-07
天津市若围药物研究所
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, single preparations such as berberine hydrochloride or sulfonylurea drugs are often used clinically to lower blood sugar in patients. Although these drugs have certain hypoglycemic effects and have certain curative effects on diabetes, if the dosage of sulfonylurea drugs If it is too large, hypoglycemia and other phenomena will often appear, especially for many diabetic syndromes, it is difficult to work

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Embodiment 1: compound hypoglycemic capsule

[0012] Each 1000 compound hypoglycemic capsules contains the following substances:

[0013] Gliclazide 20g

[0014] Berberine Hydrochloride 250g

[0015] Sodium alginate 100g

[0016] Soluble starch 72g

[0017] Alginic acid 50g

[0018] Hydroxypropyl Cellulose 5g

[0019] Magnesium Stearate 3g

[0020] According to the above prescription, the main ingredients are subjected to ultra-micronization treatment to make the fineness reach 40 μm; take 72 g of soluble starch and 20 g of gliclazide and mix them in equal increments, stir well, and then pass through a 120-mesh sieve for screening Take 50g of alginic acid and 100g of sodium alginate diester, mix them evenly, and pass through a 100-mesh sieve for screening; take 5g of hydroxypropyl cellulose and 3g of magnesium stearate, mix them evenly, and pass through a 100-mesh sieve for screening; mix the above raw and auxiliary materials Pack into...

Embodiment 2

[0021] Embodiment 2: Compound Jiangtang Tablets

[0022] Each 1000 tablets of compound hypoglycemic tablets contains the following substances:

[0023] Glibenclamide 1.25g

[0024] Berberine Hydrochloride 250g

[0025] Sodium alginate 100g

[0026] Modified starch 15g

[0027] Microcrystalline Cellulose 15g

[0028] Starch slurry (20%) 15g

[0029] Magnesium Stearate 3g

[0030] According to the above prescription, the main ingredients are firstly micronized to make the fineness reach 100 μm; the excipients are weighed and screened through a 120-mesh sieve; 15g of modified starch and 1.25g of glibenclamide are mixed in equal increments Uniformly, and screened through a 120 mesh sieve, then mixed with 250g of berberine hydrochloride, 100g of sodium alginate diester and 15g of microcrystalline cellulose for 30 minutes; 15g of starch slurry with a concentration of 20% was added to the mixed powder To make a soft material, then granulate through ...

Embodiment 3

[0031] Embodiment 3: Compound hypoglycemic granules

[0032] Each 1000 bags of compound hypoglycemic granules contains the following substances:

[0033] Glipizide 2.5g

[0034] Berberine Hydrochloride 250g

[0035] Sodium alginate 100g

[0036] Xylitol 100g

[0037] Soluble starch 25g

[0038] Hydroxypropyl Cellulose 10g

[0039] Menthol 0.05g

[0040] Starch slurry (10%) 20g

[0041] According to the above prescription, firstly, the main ingredients are subjected to ultra-micronization treatment, so that the fineness reaches 60 μm and 90 μm, each accounting for 50%; take 25 g of soluble starch and 2.5 g of glipizide and mix them uniformly in equal increments, and pass through 120 mesh Sieve and screen; get 100g xylitol and 250g berberine hydrochloride and mix, cross 100 mesh sieve and screen; get 10g hydroxypropyl cellulose and 100g sodium alginate diester mix, cross 100 mesh screen for screening; Mix the above-mentioned raw and auxili...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A compound hypoglycemic medicine in the form of tablet, capsule, particles, or powder for decreasing the sugar, pressure, fat and viscosity of blood is prepared from the fine powder of sulfonylurea medicines, the fine powder of berberine hydrochloride, biliposodium alginate, diluent, adhesive, disintegrant, lubricant, flowing aid, antisticking agent and slow releasing agent. Its advantages are high biological utilization rate, low dosage and low by-effect.

Description

technical field [0001] The invention relates to a medicine, in particular to a compound hypoglycemic medicine capable of treating diabetes. Background technique [0002] With the improvement of people's living standards, the global incidence of diabetes is increasing year by year. Diabetes has become the third major disease threatening human health after malignant tumors and cardiovascular diseases. This disease is a common endocrine disease, which is a complex disease of endocrine disorders and metabolic disorders caused by abnormal insulin function. Most patients with diabetes are accompanied by symptoms such as high blood lipids, high blood viscosity, high blood pressure, and arteriosclerosis. People with diabetes for a long time will also develop retinopathy, resulting in vision loss or even blindness. They may also experience peripheral neuropathy due to circulatory disturbance Various complications such as lower extremity ulceration. At present, berberine hydrochlor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/715A61P3/10
Inventor 张志毅刘世珍
Owner 天津市若围药物研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products